RU2015137415A - Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления - Google Patents
Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления Download PDFInfo
- Publication number
- RU2015137415A RU2015137415A RU2015137415A RU2015137415A RU2015137415A RU 2015137415 A RU2015137415 A RU 2015137415A RU 2015137415 A RU2015137415 A RU 2015137415A RU 2015137415 A RU2015137415 A RU 2015137415A RU 2015137415 A RU2015137415 A RU 2015137415A
- Authority
- RU
- Russia
- Prior art keywords
- htf
- strain
- prausnitzii
- bacteria
- composition
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims 4
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 17
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 229920001202 Inulin Polymers 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 229920001277 pectin Polymers 0.000 claims 2
- 235000010987 pectin Nutrition 0.000 claims 2
- 239000001814 pectin Substances 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 235000019722 synbiotics Nutrition 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241000235070 Saccharomyces Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims 1
- 229940107187 fructooligosaccharide Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 244000005706 microflora Species 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 229950001574 riboflavin phosphate Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000004062 sedimentation Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- -1 troches Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (23)
1. Фармацевтическая, нутрицевтическая или пищевая композиция, содержащая в качестве активного ингредиента штамм HTF-F бактерии Faecalibacterium prausnitzii (депонированной в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ) 1 марта 2013 года под номером DSM 26943) и приемлемый носитель, разбавитель или вспомогательное вещество.
2. Композиция по п. 1, содержащая жизнеспособные клетки штамма HTF-F бактерии Faecalibacterium prausnitzii (DSM 26943).
3. Композиция по п. 1, содержащая нежизнеспособные клетки штамма HTF-F бактерии Faecalibacterium prausnitzii (DSM 26943).
4. Композиция по любому из пп. 1-3, дополнительно содержащая один или более пребиотик, предпочтительно олигосахарид, более предпочтительно фруктоолигосахарид, пектин и/или инулин.
5. Композиция по любому из пп. 1-3, дополнительно содержащая одну или более пробиотическую бактерию, предпочтительно выбранную из группы, состоящей из Bifidobacterium, Lactobacillus, Streptococcus и Saccharomyces или их смесей.
6. Композиция по любому из пп. 1-3, являющаяся пищевой композицией, пищевой добавкой или нутрицевтиком.
7. Композиция по любому из пп. 1-3, являющаяся фармацевтической композицией, предпочтительно входящая в состав формы для перорального приема, предпочтительно в форме капсулы, микрокапсулы, таблетки, гранулы, порошка, пастилки, пилюли, суспензии или сиропа.
8. Штамм HTF-F бактерии F.prausnitzii (DSM 26943) для применения в качестве лекарственного средства.
9. Штамм HTF-F бактерии F.prausnitzii для применения в способе лечения или предотвращения симптомов, связанных с воспалительным заболеванием и/или дисбалансом микрофлоры желудочно-кишечного тракта субъекта, являющегося млекопитающим.
10. Штамм HTF-F бактерии F.prausnitzii для применения по п. 9, отличающийся тем, что указанный субъект является человеком.
11. Штамм HTF-F бактерии F.prausnitzii для применения по п. 9, отличающийся тем, что указанный субъект является домашним или сельскохозяйственным животным.
12. Штамм HTF-F бактерии F.prausnitzii для применения по любому из пп. 8-11, отличающийся тем, что указанную бактерию вводят субъекту в терапевтически эффективном количестве, причем предпочтительное терапевтически эффективное количество бактерии составляет примерно от 106 до 1011 KOE/день.
13. Штамм HTF-F бактерии F.prausnitzii для применения по любому из пп. 8-11, отличающийся тем, что указанное нарушение желудочно-кишечного тракта выбирают из группы, состоящей из воспалительного заболевания кишечника, болезни Крона, синдрома раздраженного кишечника, целиакии, инфекционного колита, язвенного колита и любых их комбинаций.
14. Способ получения противовоспалительной композиции, включающий этапы:
а) сбора живых клеток штамма HTF-F бактерии Faecalibacterium prausnitzii (DSM 26943) и ресуспендирования указанных клеток в подходящем буфере, предпочтительно ФСБ;
б) перемешивания ресуспендированных клеток в течение по меньшей мере 3 мин, позволяя связанному клетками внеклеточному полимерному матриксу (ВПМ) раствориться в буфере;
в) осаждения клеток центрифугированием и сбора супернатанта;
г) добавления примерно четырехкратного объема ледяного этанола к супернатанту для осаждения ВПМ;
д) промывания осажденного ВПМ этанолом;
е) необязательно последующей лиофилизации.
15. Синбиотическая композиция, содержащая живые клетки штамма HTF-F бактерии Faecalibacterium prausnitzii (DSM 26943), в смеси с (i) рибофлавином, рибофлавин фосфатом или с его физиологически приемлемой солью в количестве по меньшей мере 0,05% от общей сухой массы композиции, и (ii) цистеином, предпочтительно присутствующем в количестве по меньшей мере 0,05% от общей сухой массы композиции.
16. Синбиотическая композиция по п. 15, дополнительно содержащая инулин или фруктоолигосахариды инулинового типа, пектин предпочтительно в количестве 2-10% от общей сухой массы композиции.
17. Применение штамма HTF-F бактерии Faecalibacterium prausnitzii (DSM 26943) для получения противовоспалительной композиции.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13157830 | 2013-03-05 | ||
| EP13157830.4 | 2013-03-05 | ||
| US201361778458P | 2013-03-13 | 2013-03-13 | |
| US61/778,458 | 2013-03-13 | ||
| PCT/NL2014/050131 WO2014137211A1 (en) | 2013-03-05 | 2014-03-05 | Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015137415A true RU2015137415A (ru) | 2017-04-10 |
Family
ID=47827008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015137415A RU2015137415A (ru) | 2013-03-05 | 2014-03-05 | Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160000838A1 (ru) |
| EP (1) | EP2988761A1 (ru) |
| JP (1) | JP2016511272A (ru) |
| KR (1) | KR20150134356A (ru) |
| CN (1) | CN105228635A (ru) |
| AU (1) | AU2014226633A1 (ru) |
| BR (1) | BR112015020819A2 (ru) |
| HK (1) | HK1214954A1 (ru) |
| MX (1) | MX2015011700A (ru) |
| RU (1) | RU2015137415A (ru) |
| WO (1) | WO2014137211A1 (ru) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10548761B2 (en) * | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015013214A2 (en) | 2013-07-21 | 2015-01-29 | Whole Biome, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
| ITMI20131467A1 (it) * | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| EP2915884B1 (en) * | 2014-03-03 | 2017-12-06 | Fundacio Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | Method for diagnosing colorectal cancer from a human feces sample by quantitive PCR |
| MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| EP3212001A4 (en) | 2014-10-31 | 2018-04-25 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| HUE049340T2 (hu) * | 2014-11-13 | 2020-09-28 | Institut National De La Rech Pour Lagriculture Lalimentation Et Lenvironnement | Faecalibacterium prausnitzii törzsek gasztrointesztinális fájdalom kezelésére és megelõzésére |
| EA035925B1 (ru) | 2014-12-23 | 2020-09-01 | 4Д Фарма Рисерч Лимитед | Полипептид и иммуномодуляция |
| EP3065748B1 (en) | 2014-12-23 | 2017-11-22 | 4D Pharma Research Limited | A bacteroides thetaiotaomicron strain and its use in reducing inflammation |
| EP3255994B1 (en) | 2015-02-03 | 2020-04-08 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating arthritis |
| JP2018515426A (ja) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 細菌組成物およびその使用方法 |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CA2988693A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| JP6439037B2 (ja) | 2015-06-15 | 2018-12-19 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| MD3240554T2 (ro) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune |
| JP6529835B2 (ja) * | 2015-06-23 | 2019-06-12 | 株式会社フィス | 樹状細胞活性化剤 |
| EP3130680A1 (en) | 2015-08-11 | 2017-02-15 | Universitat de Girona | Method for the detection, follow up and/or classification of intestinal diseases |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| GB201519087D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | Method for adaption |
| RS57138B1 (sr) | 2015-11-20 | 2018-07-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ES2806424T3 (es) | 2015-12-23 | 2021-02-17 | Gervais Danone Sa | Composiciones para aumentar o mantener las poblaciones de Faecalibacterium prausnitzii |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| FR3046934B1 (fr) * | 2016-01-25 | 2018-01-26 | Institut National De La Recherche Agronomique (Inra) | Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale |
| PL3639834T3 (pl) * | 2016-02-04 | 2024-01-29 | Universiteit Gent | Zastosowanie skupisk drobnoustrojów dla zdrowia ludzi i zwierząt |
| BR112018067689A2 (pt) | 2016-03-04 | 2019-01-08 | 4D Pharma Plc | composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
| JP2019520340A (ja) * | 2016-06-01 | 2019-07-18 | クレストヴォ・ホールディングス・エルエルシー | 炎症性腸疾患（ｉｂｄ）および他の障害を治療するための組成物および方法 |
| MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| CN109874329B (zh) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | 一种产丁酸栖粪杆菌及其培养方法和应用 |
| US10799540B2 (en) | 2016-09-06 | 2020-10-13 | Bgi Shenzhen | Faecalibacterium longum and application thereof |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| EP3388069B1 (en) | 2017-04-12 | 2019-05-01 | ETH Zurich | Consortia of living bacteria useful for treatment of microbiome dysbiosis |
| EP3612199A4 (en) * | 2017-04-17 | 2021-01-06 | Baylor College of Medicine | COMMENSAL BACTERIA AS A NEW TREATMENT FOR DRY EYE AND SJÖGREN'S SYNDROME |
| MA48941A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| RS60910B1 (sr) | 2017-06-14 | 2020-11-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijski soj roda megasphaera i njihove upotrebe |
| LT3638271T (lt) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterines padermes |
| US11224622B2 (en) | 2017-06-16 | 2022-01-18 | Biofermin Pharmaceutical Co., Ltd. | Agent for preventing or treating fat-associated diseases and/or inflammation |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| CN109481473B (zh) * | 2017-09-11 | 2023-03-21 | 广州知易生物科技有限公司 | 脆弱拟杆菌提取物在制备防治肠易激综合征的药物中的应用 |
| US11491192B2 (en) | 2018-01-09 | 2022-11-08 | The Cleveland Clinic Foundation | Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria |
| WO2019139360A1 (ko) * | 2018-01-12 | 2019-07-18 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
| KR102282490B1 (ko) | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
| EP3866821B1 (en) * | 2018-10-15 | 2024-02-28 | PharmaBiome AG | Consortia of living bacteria useful for treatment of colorectal cancer |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
| KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
| KR102169795B1 (ko) | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
| US20230293600A1 (en) * | 2020-08-14 | 2023-09-21 | Kobiolabs, Inc. | Faecalibacterium prausnitzii strain and uses there of |
| KR102185828B1 (ko) | 2020-08-26 | 2020-12-03 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물 |
| WO2022065957A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 천랩 | 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물 |
| CN117119907A (zh) * | 2021-05-06 | 2023-11-24 | 雀巢产品有限公司 | 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 |
| CN113797232B (zh) * | 2021-10-28 | 2023-05-26 | 南昌大学 | 具有缓解胰岛素抵抗功能的组合物及其应用 |
| CN115074277B (zh) * | 2022-06-24 | 2023-09-26 | 无锡特殊食品与营养健康研究院有限公司 | 一株可缓解肥胖的普拉梭菌及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012016982B8 (pt) | 2010-01-14 | 2022-12-20 | Institut National De Rech Pour Lagriculture Lalimentation Et Lenvironnement | bactéria de ácido lático recombinante de grau alimentício e composição terapêutica |
| NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
-
2014
- 2014-03-05 WO PCT/NL2014/050131 patent/WO2014137211A1/en active Application Filing
- 2014-03-05 AU AU2014226633A patent/AU2014226633A1/en not_active Abandoned
- 2014-03-05 KR KR1020157027308A patent/KR20150134356A/ko not_active Application Discontinuation
- 2014-03-05 JP JP2015561299A patent/JP2016511272A/ja active Pending
- 2014-03-05 CN CN201480012892.5A patent/CN105228635A/zh active Pending
- 2014-03-05 BR BR112015020819A patent/BR112015020819A2/pt active Search and Examination
- 2014-03-05 US US14/772,519 patent/US20160000838A1/en not_active Abandoned
- 2014-03-05 EP EP14709437.9A patent/EP2988761A1/en not_active Withdrawn
- 2014-03-05 RU RU2015137415A patent/RU2015137415A/ru not_active Application Discontinuation
- 2014-03-05 MX MX2015011700A patent/MX2015011700A/es unknown
-
2016
- 2016-03-14 HK HK16102935.6A patent/HK1214954A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2988761A1 (en) | 2016-03-02 |
| KR20150134356A (ko) | 2015-12-01 |
| HK1214954A1 (zh) | 2016-08-12 |
| MX2015011700A (es) | 2016-07-20 |
| US20160000838A1 (en) | 2016-01-07 |
| AU2014226633A1 (en) | 2015-09-03 |
| BR112015020819A2 (pt) | 2017-07-18 |
| WO2014137211A1 (en) | 2014-09-12 |
| CN105228635A (zh) | 2016-01-06 |
| JP2016511272A (ja) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015137415A (ru) | Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления | |
| Yahfoufi et al. | Role of probiotics and prebiotics in immunomodulation | |
| Van Der Aa et al. | Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence | |
| KR102656709B1 (ko) | 장 감염과 염증의 치료 및 예방을 위한 조성물 및 방법 | |
| CA2497989C (en) | Probiotic bacterium: lactobacillus fermentum | |
| HRP20180152T1 (hr) | Sojevi bakterija koji su izolirani iz svinja | |
| JP6235138B2 (ja) | プレバイオティクス効果を有する組成物 | |
| RU2017120146A (ru) | Штаммы Lactobacillus или Bifidobacterium для поддержания гомеостаза | |
| Cabana et al. | Probiotics in primary care pediatrics | |
| JP2017537156A5 (ru) | ||
| JP2012520325A5 (ru) | ||
| RU2013148474A (ru) | Пребиотические бактериальные штаммы и симбиотическая композиция, содержащая эти штаммы, для детского питания | |
| JP2013139462A5 (ru) | ||
| RU2012111253A (ru) | Bifidobacterium longum и функциональные расстройства желудочно-кишечного тракта | |
| Liu et al. | Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation | |
| e Silva et al. | Development of probiotic tablets using microparticles: viability studies and stability studies | |
| Rigo-Adrover et al. | A fermented milk concentrate and a combination of short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides/pectin-derived acidic oligosaccharides protect suckling rats from rotavirus gastroenteritis | |
| RU2016129178A (ru) | Lactobacillus salivarius для лечения мастита | |
| Maurya et al. | Probiotics: an approach towards health and disease | |
| RU2015152826A (ru) | Композиции, содержащие смесь бактерий, включающую педиококк и лактобактерии, и способы для уменьшения эффектов алкоголя | |
| Pai et al. | Microbes in the gut: a digestable account of host-symbiont interactions | |
| KR20240037257A (ko) | 위장관 장애의 치료에서의 사용을 위한 생리학적으로 허용되는 효모 조성물 | |
| Yang et al. | Strategies for applying probiotics in the antibiotic management of Clostridioides difficile infection | |
| CN115299610B (zh) | 一种肠道益生菌组合物及其应用 | |
| Mc Anto Antony et al. | The Role of Gut Microbiome Supplementation in COVID-19 Management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20170508 |